Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bismuth hydroxide is an inorganic compound primarily utilized as an active pharmaceutical ingredient (API) in the production of gastrointestinal medications. As a member of the bismuth salt family, it is employed for its antacid and gastroprotective properties. The therapeutic effect of bismuth compounds typically involves the formation of a protective coating over gastric ulcers and mucosal erosions, which shields the tissue from gastric acid and pepsin. Additionally, bismuth salts exhibit direct bactericidal activity against *Helicobacter pylori* by inhibiting bacterial enzymes and cell wall synthesis. Zhejiang Xinmingzhu Pharmaceutical manufactures bismuth hydroxide as a raw material for export and for use in oral solid dosage forms, categorizing it as a commodity generic or over-the-counter (OTC) chemical rather than a novel biotech candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bismuth hydroxide.